Jelena Roganovic https://orcid.org/0000-0002-7960-6069
REFERENCES
1. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel) . 2018;10(10):380.
2. Fernandes CJ, Morinaga LTK, Alves JL Jr, et al. Cancer-associated thrombosis: the when, how and why. Eur Respir Rev.2019;28(151):180119.
3. Ko RH, Thornburg CD. Venous Thromboembolism in Children with Cancer and Blood Disorders. Front Pediatr . 2017;5:12.
4. Athale UH, Yang JYK, Chan AKC. Thromboembolism in children with cancer. In: UpToDate, Pappo AS, O’Brien S (Eds), UpToDate, Waltham, MA. (Last updated on May 17, 2021; Accessed on February 02, 2022.)
5. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-1008.
6. Barg AA, Kenet G. Cancer-associated thrombosis in pediatric patients.Thromb Res. 2020;191 Suppl 1:S22-S25.
7. Kujovich JL. GeneReviews. Seattle (WA): University of Washington, Seattle; 2018. Factor V Leiden thrombophilia.
8. Kujovich JL. GeneReviews. Seattle (WA): University of Washington, Seattle; 2006. Prothrombin-related thrombophilia.
9. Rosenson RS, Smith CC, Bauer KA. Overview of homocysteine. In: UpToDate, Freeman MW (Ed), UpToDate, Waltham, MA. (Last updated on December 06, 2021; Accessed on February 21, 2022.)
10. Alfirevic Z, Simundic AM, Nikolac N, et al. of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case-control study. Bioch Med. 2010;20(2):229-235.
11. Coen D, Zadro R, Honovic L, Banfic L, Stavljenic Rukavina A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.Croat Med J. 2001;42(4):488-492.
12. Akin DF, Sipahi K, Kayaalp T, et al. Factor V Leiden and prothrombin 20210A mutations among Turkish pediatric leukemia patients. Leuk Res Treatment. 2012;2012:345-349.
13. Nowak-Göttl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with ALL carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93(5):1595-1599.
14. Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with ALL.Blood Coagul Fibrinolysis. 2001;12(5):367-70.
15. Pihusch R, Danzl G, Scholz M, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer. 2002;94(12):3120-3126.
16. Eroglu A, Ulu A, Cam R, Kurtman C, Akar N. Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. J Thromb Thrombolysis.2007;23(1):31-34.
17. Battistelli S, Stefanoni M, Genovese A, Vittoria A, Cappelli R, Roviello F. Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol.2006;12(26):4179-4180.
18. Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H. Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol. 2011;29(13):1722-1727.
19. Paspatis GA, Sfyridaki N, Papanikolaou N, et al. Resistance to activated protein C, Factor V Leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb.2002;32:2-7.
20. Martinelli I, Ponziani FR, Maino A, et al Thrombosis after liver transplantation for hepatocellular carcinoma. PLoS One.2017;12(10):e0186699.
21. Albisetti M, Chan AKC. Venous thrombosis and thromboembolism (VTE) in children: Risk factors, clinical manifestations, and diagnosis. In: UpToDate, O’Brien S (Ed), UpToDate, Waltham, MA. (Last updated on February 03, 2022; Accessed on February 12, 2022.)
22. Tuckuviene R, Christensen AL, Helgestad J, Johnsen SP, Kristensen SR. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr.2011;159(4):663-669.
23. Takemoto CM, Sohi S, Desai K, et al. Hospital-associated venous thromboembolism in children: incidence and clinical characteristics.J Pediatr. 2014;164(2):332-338.
24. Giordano P, Grassi M, Saracco P, et al; Paediatric Thrombosis Working Group of the RITI. Paediatric venous thromboembolism: a report from the Italian Registry of Thrombosis in Children (RITI). Blood Transfus. 2018;16(4):363-370.
25. Jinks S, Arana A. Venous thromboembolism in paediatrics. BJA Educ. 2019;19(9):305-312.
26. Athale UH, Chan AK. Thromboembolic complications in pediatric hematologic malignancies. Semin Thromb Hemost.2007;33(4):416-426.
27. Lipay NV, Zmitrovich AI, Aleinikova OV. Epidemiology of venous thromboembolism in children with malignant diseases: a single-center study of the Belarusian Center for Pediatric Oncology and Hematology.Thromb Res. 2011;128(2):130–134.
28. Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer.Pediatr Blood Cancer. 2008;51(6):792-797.
29. Pelland-Marcotte MC, Pole JD, Kulkarni K, et al. Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study. Thromb Haemost. 2018;118(9):1646-1655.
30. Athale U, Cox S, Siciliano S, Chan AK. Thromboembolism in children with sarcoma. Pediatr Blood Cancer. 2007;49(2):171-176.
31. Schiavetti A, Foco M, Ingrosso A, Bonci E, Conti L, Matrunola M. Venous thrombosis in children with solid tumors. J Pediatr Hematol Oncol. 2008;30(2):148-152.
32. Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS. Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol. 2007;25(12):1519-1524.
33. Piovesan D, Attard C, Monagle P, Ignjatovic V. Epidemiology of venous thrombosis in children with cancer. Thromb Haemost.2014;111:1015–1021.
34. Athale UH, Nagel K, Khan AA, Chan AK. Thromboembolism in children with lymphoma. Thromb Res. 2008;122(4):459-465.
35. Tabori U, Beni-Adani L, Dvir R, et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer. 2004;43(6):633-636.
36. Castle J, Blower E, Kirwan CC. Update on the role of circulating tumour cells in cancer-associated thrombosis. Thrombosis Update.2021;5:100066.
37. Rubio-Jurado B, Sosa-Quintero LS, Guzmán-Silahua S, García-Luna E, Riebeling-Navarro C, Nava-Zavala AH. The prothrombotic state in cancer.Adv Clin Chem. 2021;105:213-242.
38. Spavor M, Halton J, Dietrich K, et al. Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model. Thromb Res. 2016;144:27-31.
39. Prasca S, Carmona R, Ji L, et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric ALL.Thromb Res. 2018;165:44-50.
40. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood ALL: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood.2006;108(7):2216-2222.
41. Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Semin Thromb Hemost. 2007;33(4):416-426.
42. Albisetti M, Kellenberger CJ, Bergsträsser E, et al. Port-a-cath-related thrombosis and postthrombotic syndrome in pediatric oncology patients. J Pediatr. 2013;163(5):1340-1346.
43. Wiegering V, Schmid S, Andres O, et al. Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience. BMC Hematol. 2014;14(1):18.
44. Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost. 2008;6(1):70-75.
45. Schoot RA, van de Wetering MD, et al; DCOG-Aristocaths Supportive Care Working Group. Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters. Pediatr Blood Cancer. 2016;63(8):1438-1444.
46. Musgrave KM, van Delft FW, Avery PJ, et al. Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia – a cohort study from the United Kingdom. Br J Haematol. 2017;179(4):667-669.
47. Ranta S, Tuckuviene R, Mäkipernaa A, et al. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. Br J Haematol. 2015;168(4):547-552.
48. Ghanem KM, Dhayni RM, Al-Aridi C, et al. Cerebral sinus venous thrombosis during childhood ALL therapy: Risk factors and management.Pediatr Blood Cancer. 2017;64(12):e26694.
49. El-Khoury H, Saifi O, Haddad S, et al. Treatment-induced cerebral sinus venous thrombosis in childhood acute lymphoblastic malignancies: New risk factors to consider. Pediatr Blood Cancer.2021;68(11):e29210.
50. Athale UH, Chan AK. Thrombosis in children with ALL: part I. Epidemiology of thrombosis in children with ALL. Thromb Res.2003;111(3):125-131.
51. Decousus H, Moulin N, Quenet S, et al. Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res. 2007;120 Suppl 2:S51-61.
52. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb. 2008;36(3-4):131-136.
53. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J.2006;4:15.
54. Knöfler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy–impact of central venous lines. Eur J Pediatr.1999;158 Suppl 3:S147-150.
55. Ünal S, Varan A, Yalçin B, Büyükpamukçu M, Gürgey A. Evaluation of thrombotic children with malignancy. Ann Hematol.2005;84(6):395-399.
56. Barzilai-Birenboim S, Nirel R, Arad-Cohen N, et al. Venous Thromboembolism and Its Risk Factors in Children with ALL in Israel: A Population-Based Study. Cancers (Basel). 2020;12(10):2759.
57. Sifontes MT, Nuss R, Hunger SP, Wilimas J, Jacobson LJ, Manco-Johnson MJ. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol . 1997;96(3):484-489.
58. Ruud E, Holmstrøm H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer–a prospective study. Med Pediatr Oncol. 2002;38(6):405-410.
59. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with ALL treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost. 2000;83(6):840-843.
60. Mitchell LG, Andrew M, Hanna K, et al; Prophylactic Antithrombin Replacement in Kids with ALL Treated with Asparaginase Group (PARKAA). A prospective cohort study determining the prevalence of thrombotic events in children with ALL and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with ALL Treated with Asparaginase (PARKAA) Study. Cancer.2003;97(2):508-516.